Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01565694 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
A Phase 3 study, sponsored by Astellas Pharma Europe B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 76
- Enrollment target
NCT01565694 is a Phase 3 study that has completed, run by Astellas Pharma Europe B.V.. The registered enrollment target is 76 participants.
The verdict
NCT01565694, a Phase 3 study, has completed, sponsored by Astellas Pharma Europe B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of this study was to investigate a medicine for the treatment of symptoms and complications of neurogenic detrusor overactivity (NDO) in children and adolescents.
Interventions
- DRUG Solifenacin succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2012-08-14 |
| Est. Completion | 2016-04-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01565694
The ClinicalTrials.gov registry entry for NCT01565694 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Europe B.V., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Solifenacin succinate is the first listed.
NCT01565694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01565694 about?
NCT01565694 is a clinical study titled "A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity". The purpose of this study was to investigate a medicine for the treatment of symptoms and complications of neurogenic detrusor overactivity (NDO) in children and adolescents.
What is the current status of trial NCT01565694?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 76 participants. The study started on 2012-08-14. Estimated completion is 2016-04-28.
What interventions are being tested in trial NCT01565694?
The interventions under investigation include: Solifenacin succinate (DRUG).
Who is sponsoring clinical trial NCT01565694?
This trial is sponsored by Astellas Pharma Europe B.V., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.